Net Worth Advisory Group Buys Shares of 5,054 Merus (NASDAQ:MRUS)

Net Worth Advisory Group purchased a new position in Merus (NASDAQ:MRUS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,054 shares of the biotechnology company's stock, valued at approximately $213,000.Other institutional investors also recently modified their holdings of the company. State of New Jersey Common Pension Fund D raised its stake in Merus by 29.0% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 48,268 shares of the biotechnology company's stock worth $2,030,000 after buying an additional 10,842 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Merus in the 4th quarter valued at about $347,000. Wells Fargo & Company MN boosted its position in shares of Merus by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 300 shares in the last quarter. Northern Trust Corp lifted its stake in Merus by 61.2% in the fourth quarter. Northern Trust Corp now owns 76,335 shares of the biotechnology company's stock valued at $3,210,000 after buying an additional 28,983 shares during the period. Finally, Baker BROS. Advisors LP boosted its holdings in shares of Merus by 50.0% during the 4th quarter. Baker BROS. Advisors LP now owns 450,000 shares of the biotechnology company's stock worth $18,922,000 after buying an additional 150,000 shares in the last quarter. 96.14% of the stock is owned by institutional investors. Merus Trading Down 1.4%Shares of NASDAQ MRUS opened at $54.61 on Friday. The stock has a fifty day simple moving average of $46.42 and a two-hundred day simple moving average of $44.30. Merus has a 1-year low of $33.19 and a 1-year high of $62.98. The firm has a market cap of $3.78 billion, a price-to-earnings ratio of -13.83 and a beta of 1.04. Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The firm had revenue of $26.49 million for the quarter, compared to analysts' expectations of $7.82 million. Analysts forecast that Merus will post -3.85 EPS for the current year. Wall Street Analyst Weigh InSeveral research analysts have weighed in on the stock. HC Wainwright restated a "buy" rating and set a $85.00 price objective on shares of Merus in a report on Monday, March 3rd. William Blair reissued an "outperform" rating on shares of Merus in a research report on Monday, April 28th. Bank of America dropped their price target on shares of Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Guggenheim reiterated a "buy" rating and set a $109.00 price target on shares of Merus in a research note on Friday, March 28th. Finally, BMO Capital Markets set a $110.00 price objective on Merus and gave the stock an "outperform" rating in a research note on Friday, May 23rd. Thirteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $85.83.Check Out Our Latest Report on MerusMerus Profile (Free Report)Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.Featured StoriesFive stocks we like better than Merus3 Best Fintech Stocks for a Portfolio BoostIBM Up 10 Days in a Row: What’s Driving the Winning Streak?TSX Venture Exchange (Formerly Canadian Venture Exchange)Upstart Stock’s Bull Case Just Got a Lot StrongerGolden Cross Stocks: Pattern, Examples and Charts Higher Gulf Oil Output Puts These Energy Names in PlayWant to see what other hedge funds are holding MRUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merus (NASDAQ:MRUS - Free Report).This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Merus Right Now?Before you consider Merus, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here